China Nod At Regulatory Improvements Will Widen Doors For US Medtech
This article was originally published in Clinica
Executive Summary
Chinese officials have agreed to address regulatory challenges to improve access for US firms to China's medical device market following talks with American counterparts and medical device industry representatives. The targeted reforms include lowering clinical trial barriers for some class II and class III devices.
You may also be interested in...
China's Medtech Regulatory Reforms Yet To Enter Steady Path
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.